Replies to post #106074 on Mohacsy's Safe Portfolio Member Forum

[Elroy Jetson]

Pfizer PFE will complete a $31 billion debt offering tomorrow, to fund its pending $43 billion acquisition of (ADC) antibody-drug conjugate maker, Seagen SGEN. The bond sale is one of the largest debt offerings of all time.


Seagen has four approved drugs and a large pipeline of additional cancer ADCs - https://www.seagen.com/science/pipeline

The acquisition for $229 per share, an 18% premium to the current SGEN price, should gain regulatory approval and close later this year.

SGEN will immediately increase Pfizer's revenue, up $30 billion by 2030, and will be initially slightly profit accretive, which will grow over time.


Seagen was founded in 1998 as Seattle Genetics.